All In MedTech

Device Trial Radar · NCT02974816

Glooko mHealth Advantage Study

The Glooko Diabetes Mobile Monitoring and Management Advantage Study

Last checked: Nov 20, 2026Latest source record: Jun 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

197

Actual

Start

May 15, 2017

Primary completion

Apr 17, 2020

Study completion Apr 17, 2020

Sponsor

Lead sponsor
GlookoNot on our public-company list
Sponsor type
Industry
First posted
Nov 28, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Glooko's mobile applicationDevice

    Standard of care and Remote monitoring

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c from baselineTime frame: 24 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • John Muir Physician Network Clinical Research Center

    Concord, California

  • Sutter Health

    Elk Grove, California

  • Scripps Whittier Diabetes Institute

    San Diego, California

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.